454678-91-2

Basic information

• Product Name: 4-(1,3-Thiazol-2-yl)benzyl alcohol
• Synonyms: [4-(1,3-Thiazol-2-yl)phenyl]methanol;4-(1,3-Thiazol-2-yl)benzyl alcohol;4-(1,3-Thiazol-2-yl)benzyl alcohol 97%;2-(3-Hydroxymethylphenyl)oxazole-4-carboxylic acid methyl ester;2-(3-Hydroxymethylphenyl)oxazole-5-carboxylic acid ethyl ester;2-(4-Hydroxymethylphenyl)oxazole-4-carboxylic acid methyl ester;2-(4-Hydroxymethylphenyl)oxazole-5-carboxylic acid ethyl ester;3-(Thiazol-2-yl)benzyl alcohol
• CAS NO: 454678-91-2
• Molecular Formula: C₁₀H₉NOS
• Molecular Weight: 191.24956
• Mol File: 454678-91-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 93.5-97
• Boiling Point: 363.9 °C at 760 mmHg
• Flash Point: 173.9 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 6.19E-06mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 4-(1,3-Thiazol-2-yl)benzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3-Thiazol-2-yl)benzyl alcohol(454678-91-2)
• EPA Substance Registry System: 4-(1,3-Thiazol-2-yl)benzyl alcohol(454678-91-2)

Safety Data

• Hazardous Substances Data: 454678-91-2(Hazardous Substances Data)

Usage

General Description

4-(1,3-Thiazol-2-yl)benzyl alcohol is a chemical compound with the molecular formula C11H11NOS. It is a benzyl alcohol derivative with a thiazole ring attached to the benzene ring. 4-(1,3-Thiazol-2-yl)benzyl alcohol is commonly used as a building block in organic synthesis and pharmaceutical research. It has been found to exhibit antimicrobial and antifungal properties, making it a potential candidate for the development of new drugs. Additionally, 4-(1,3-Thiazol-2-yl)benzyl alcohol is also used in the production of fragrances and flavors due to its aromatic properties. Overall, this chemical compound has a wide range of potential applications in various industries.

InChI:InChI=1/C10H9NOS/c12-7-8-1-3-9(4-2-8)10-11-5-6-13-10/h1-6,12H,7H2

Upstream product

• 198904-53-9 4-(thiazol-2-yl)-benzaldehyde 
• 130534-91-7 1-bromo-4-[(methoxymethyloxy)methyl]benzene 
• 873-75-6 4-bromobenzenemethanol 
• 454678-92-3 4-[(methoxymethyloxy)methyl]-phenylboric acid 
• 3034-53-5 2-bromo-1,3-thiazole 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 454678-93-4 2-{4-[(methoxymethyloxy)methyl]phenyl}thiazole 

Downstream Products

• 906352-61-2 2[4-(chloromethyl)phenyl]-1,3-thiazole 
• 1273387-13-5 docosyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-yl-amino)acetate 
• 1273387-11-3 [2-(morpholin-4-yl)ethyl] (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-09-9 pivaloyloxymethyl (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-07-7 {2-[2-(2-hydroxyethoxy)ethoxy]ethyl} (6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetate 
• 1273387-06-6 2-{2-[2-(benzyloxy)ethoxy]ethoxy}ethyl 2-({6-[(N-{[4-(1,3-thiazol-2-yl)phenyl]methyl}pyridine-2-sulfonamido)methyl]pyridin-2-yl}amino)acetate 
• 1273387-05-5 N,N-dimethyl-2-(6-{(pyridin-2-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetamide 
• 1187450-75-4 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)-acetic acid trifluoroacetate 
• 1187450-50-5 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}pyridin-2-ylamino)acetic acid hydrochloride 
• 1187450-46-9 (6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]aminomethyl}-pyridin-2-ylamino)acetic acid 
• 1187451-27-9 2-{4-[bis(tert-butoxycarbonyl)aminomethyl]phenyl}thiazole 
• 1187450-47-0 tert-butyl [tert-butoxycarbonyl(6-{(pyridin-3-ylsulfonyl)[4-(thiazol-2-yl)benzyl]-aminomethyl}pyridin-2-yl)amino]acetate 
• 1187451-26-8 4-(thiazol-2-yl)benzyl bromide 
• 1083364-05-9 C₁₀H₈FNOS 

Relevant articles and documents

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independe

PYRIDYLAMINOACETIC ACID COMPOUND

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl